Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing Operations and Provides 2017 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Charles River Labs (CRL) PT Raised to $84 at UBS Following Strong 4Q Results
February 15, 2017 9:31 AM ESTUBS analyst Jonathan Groberg maintains Sell rating and raises price target on Charles River Laboratories International (NYSE: CRL) to $84 (from $78), as the company announced revenue and EPS figures above consensus projections.
Groberg comments, "CRL reported 4Q16 results with reported revenue of $467m,... More
Charles River Labs (CRL) PT Raised to $104 at Jefferies Following Strong 4Q Results
February 15, 2017 8:11 AM ESTJefferies analyst David Windley reiterates Buy rating and raises price target on Charles River Laboratories (NYSE: CRL), as the company reported 2016 fourth quarter revenue and EPS above consensus.
Windley comments, "4Q results far outpaced consensus revenue/EPS driven by strength across the 3 segments.... More
Charles River Laboratories (CRL) Tops Q4 EPS by 10c, Guides FY17 EPS In-Line
February 14, 2017 6:33 AM ESTCharles River Laboratories (NYSE: CRL) reported Q4 EPS of $1.21, $0.10 better than the analyst estimate of $1.11. Revenue for the quarter came in at $466.8 million versus the consensus estimate of $441.64 million.
GUIDANCE:
Charles River Laboratories sees FY2017 EPS of $5.00-$5.10, versus the... More
